# Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT02699879** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1009 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Pirfenidone

## Key facts

- **NCT ID:** NCT02699879
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-16
- **Primary completion:** 2016-09-15
- **Final completion:** 2016-09-15
- **Target enrollment:** 1009 (ACTUAL)
- **Last updated:** 2017-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02699879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02699879, "Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02699879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*